Baird analyst Michael Ulz reiterated an Outperform rating and $75.00 price target on Ultragenyx Pharma (NASDAQ: RARE), saying they are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE